PLoS ONE · 2012 · 32 citations · 40 references
MedicineNephrologyPharmacotherapyKidney TransplantationRenal PathologyRenal PathophysiologyGlomerular PathophysiologyImmunosuppression In Kidney TransplantationMtor Inhibitor TherapyRenal DiseaseRenal FibrosisRenal Function TestsEverolimus TreatmentKidney Disease Progression ModelingMtor InhibitionMtor SignalingPost-transplant ProteinuriaProteinuria ReductionRenal Fibrosis MechanismsSurgical Nephrectomy
BACKGROUND: The immunosuppressive mammalian target of rapamycin (mTOR) inhibitors are widely used in solid organ transplantation, but their effect on kidney disease progression is controversial. mTOR has emerged as one of the main pathways regulating cell growth, proliferation, differentiation, migration, and survival. The aim of this study was to analyze the effects of delayed inhibition of mTOR pathway with low dose of everolimus on progression of renal disease and TGFβ expression in the 5/6 nephrectomy model in Wistar rats. METHODS: This study evaluated the effects of everolimus (0.3 mg/k/day) introduced 15 days after surgical procedure on renal function, proteinuria, renal histology and mechanisms of fibrosis and proliferation. RESULTS: Everolimus treated group (EveG) showed significantly less proteinuria and albuminuria, less glomerular and tubulointerstitial damage and fibrosis, fibroblast activation cell proliferation, when compared with control group (CG), even though the EveG remained with high blood pressure. Treatment with everolimus also diminished glomerular hypertrophy. Everolimus effectively inhibited the increase of mTOR developed in 5/6 nephrectomy animals, without changes in AKT mRNA or protein abundance, but with an increase in the pAKT/AKT ratio. Associated with this inhibition, everolimus blunted the increased expression of TGFβ observed in the remnant kidney model. CONCLUSION: Delayed mTOR inhibition with low dose of everolimus significantly prevented progressive renal damage and protected the remnant kidney. mTOR and TGFβ mRNA reduction can partially explain this anti fibrotic effect. mTOR can be a new target to attenuate the progression of chronic kidney disease even in those nephropathies of non-immunologic origin.
40
Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex
Dos D. Sarbassov, David A. Guertin, Siraj M. Ali et al. · Science · 2005 · 6.2K citations
Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB
Dos D. Sarbassov, Siraj M. Ali, Shomit Sengupta et al. · Molecular Cell · 2006 · 2.6K citations · Full text
The Natural History of Chronic Allograft Nephropathy
Brian J. Nankivell, Richard Borrows, Caroline Fung et al. · New England Journal of Medicine · 2003 · 1.9K citations · Full text